Cellular Reprogramming Tools Market Size, Share, and COVID-19 Impact Analysis By Type (Episomal Reprogramming, RNA Reprogramming, Retrovirus Reprogramming, Lentivirus Reprogramming, Sendai Virus-based Reprogramming, and Others), By Application (Research and Therapeutic), By End-user (Research & Academic Institutes and Biotechnology & Pharmaceutical Companies), and Region Forecast, 2024-2032

Cellular reprogramming is a method of converting mature, specialized cells into induced pluripotent stem cells, also known as iPS cells. These tools used for cellular reprogramming hold great potential for tissue regeneration and repair, to replace lost cells due to injuries or diseases.  Growing demand for personalized medicines and the increasing clinical studies for the use of induced pluripotent stem cells (iPSCs) in drug discovery and development are the key factors contributing to the growth of the cellular reprogramming tools market.

• For instance, in July 2020, Fate Therapeutics announced FDA clearance of an Investigational New Drug (IND) application for the first-ever iPSC-derived CAR T-Cell Therapy. The company planned to initiate a phase 1 clinical study for patients with advanced B-cell leukemias and lymphomas.

Furthermore, pharmaceutical industries are heavily investing in developing an iPSC approach to generate effective cell sources to enable drug screening and toxicity assessment, which is expected to increase the demand for the cellular reprogramming tools market.

• For instance, in October 2021, Curi Bio, Inc., a manufacturer of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL Co., Ltd., a manufacturer of induced pluripotent stem cell (iPSC) technology, announced the formation of Celogics, Inc., a joint venture to develop leading iPSC-derived cell products.

However, the high cost of investment in research and development activities and more stringent restrictions for product approvals are factors expected to hamper the market's growth to a certain extent.

Impact of COVID-19 on the Cellular Reprogramming Tools Market

The cellular reprogramming tools market witnessed a positive impact in 2020 during the COVID-19 pandemic due to increased demand for reprogramming methods for producing personalized medicines.

iPSCs are an effective resource for creating normal, relevant cell types for SARS-CoV2. Moreover, researchers are engaged in the development of novel medications and treatments to fight against the pandemic.

• For instance, according to a research study published by the U.K. Health Security Agency, iPSC-derived organoids have been used for modelling SARS-CoV-2 infection in various organs, including the kidney, lung, liver, intestine, and blood vessels.

Furthermore, the increasing investments from private players and the government in this space are anticipated to impact the market's growth in the near future significantly.

Key Insights

The report will cover the following key insights:

• Prevalence of Chronic Diseases - by Key Countries/Regions, 2021/2022.


• Clinical Trials involving Pluripotent Stem Cells.


• Technological Advancements in the Market.


• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.).


• Impact of COVID-19 on the Market.

Analysis by Type

Based on type, the RNA reprogramming segment accounted for a significant proportion of the global cellular reprogramming tools market in 2022. RNA reprogramming type generates the highest quality human iPS cell lines from somatic tissue. The technology is easy to use and provides a reprogramming efficiency of better than 1% compared to other types. The growth of the segment was mainly attributed to the constant innovation and the development of RNA reprogramming kits to provide a more effective way to reprogram patient samples.

• For instance, the latest evolution in Stemgent RNA reprogramming, the StemRNA 3rd Gen Reprogramming Kit (formerly called the StemRNA-NM Reprogramming Kit) launched by REPROCELL Inc., combines non-modified RNA and microRNA technology to provide a kit for stem cell researchers to reprogram patient samples effectively.

Furthermore, the increasing application of RNA reprogramming in disease modeling, drug screening, cell transplantation therapies, and regenerative medicines is projected to drive the growth of this segment over the forecast period.

Moreover, due to the higher patient adoption rate, the Sendai virus-based reprogramming segment is projected to grow at a significant CAGR over the forecast period. In addition, Sendai virus-based reprogramming method is widely used in clinical studies of gene therapy and vaccine delivery. Thus, influencing the segmental growth over the forecast period.

Regional Analysis

North America dominated the cellular reprogramming tools market in 2022 and is projected to maintain its position over the forecast period. The growth is mainly attributed to the ongoing technological advancements in iPSC and an increasing number of manufacturing facilities for cell therapy in the U.S.

• For instance, in April 2022, Kite, a Gilead Sciences, Inc. company, received U.S. FDA approval for its CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site produces Kite’s FDA-approved CAR T-cell therapy to treat blood cancer. This has increased Kite’s manufacturing capacity by 50% to meet patient demand for new cancer therapies.

In addition, factors such as high throughput drug toxicity analysis, expanding knowledge of iPSC platform, and the rising level of research and development are influencing the growth of the market in North America.

The market for cellular reprogramming tools in Asia Pacific is expected to grow significantly over the forecast period. The growth is mainly attributed to the increased adoption of cell reprogramming technologies in the region. In addition, expanding the medical development framework and better healthcare infrastructure in emerging economies such as Australia and India is projected to create lucrative growth opportunities for the market in the region.

Key Players Covered

The report will include the profiles of key players such as Thermo Fisher Scientific, Alstem, Inc., Amerigo Scientific, STEMCELL Technologies, Merck KGaA, Creative Bioarray, REPROCELL Inc., ESI BIO, BioVision Inc., Allele Biotech, and others.

Segmentation

Key Industry Developments

• May 2022: bit.bio, a synthetic biology company focused on developing human cell type launched their ioGlutamatergic Neurons HTT50CAG/WT cells to advance research and accelerate drug discovery for Huntington’s disease.


• June 2021: Catalent announced that it had acquired RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). This acquisition has strengthened Catalent’s portfolio of induced pluripotent stem cell-based therapies.